anonymous
Guest
anonymous
Guest
Otezla up for grabs. Why not add it to our kit??
We already have a product that competes against it
Sun doesn’t have the capital to buy it
We can barely make payroll! You think we can con someone into loaning us $10 billion.
What product? Iluyma?
Janssen has Stelara and Tremfya, Abbvie has Humira and Sky
First off, Sun can't afford Otezla. They don't have the capital. Second, if Sun did buy Otezla, they would run the entire franchise into the ground within 6 months.
We can have an oral and an injectable. Other companies have 2
Sun had to raid the Taro coffers for a few hundred million to cover some basic costs.
Well said !!!Yes, and now we at Taro have to suffer low bonuses because you azzholes can't sell your products or file a simple state license in time before the deadline.